Pertussinum

The dosage of Human Sputum, Bordetella Pertussis Infected is highly individualized and depends strictly on the intended use (diagnostic vs. therapeutic) and the specific concentration of the standardized extract.

• For Diagnostic Skin Testing: The typical dose is 0.02 mL to 0.1 mL of a highly diluted (e.g., 1:100 or 1:1000) extract administered via intradermal injection. Healthcare providers will usually start with the lowest possible concentration to avoid a systemic reaction.
• For Immunological Provocation: In specialized research settings, doses may range from 0.1 mL to 0.5 mL of a standardized concentration, administered subcutaneously.
• Standardized Units: Dosing is often expressed in Protein Nitrogen Units (PNU) or Bioequivalent Allergy Units (BAU) rather than milligrams. A common range might be 100 to 5000 PNU, depending on the patient's sensitivity profile.

Human Sputum, Bordetella Pertussis Infected is rarely used in pediatric populations unless specifically indicated for advanced immunological assessment.

• Ages 12 and older: Dosing is generally similar to adult dosing but may be adjusted based on the child's body surface area and known sensitivity history.
• Ages 0 to 11: Safety and efficacy have not been firmly established in this age group for most standardized extracts of this nature. If used, it must be under the direct supervision of a pediatric immunologist, with doses often reduced by 50-75% of the adult starting dose.

Renal Impairment

No specific dosage adjustments are typically required for renal impairment, as the product is primarily processed through proteolytic degradation. However, patients with end-stage renal disease (ESRD) may have altered immune responses, which can affect the interpretation of diagnostic tests.

Hepatic Impairment

No dosage adjustments are required for hepatic impairment. The liver does not play a primary role in the clearance of these biological proteins.

Elderly Patients

Geriatric patients (65 years and older) may exhibit 'immunosenescence' (a natural decline in immune function). Healthcare providers may need to use higher concentrations for diagnostic testing to achieve a visible reaction, though caution is advised due to the increased risk of systemic sensitivity.

This medication is not self-administered. It must be given by a healthcare professional in a clinical setting equipped with emergency resuscitation equipment.

1. 1Preparation: The healthcare provider will inspect the vial for particulate matter or discoloration. If the product is lyophilized, it will be reconstituted gently without vigorous shaking to prevent protein denaturation.
2. 2Administration: For skin testing, the skin (usually the volar aspect of the forearm) is cleaned with alcohol. The extract is injected intradermally to create a small 'wheal' or 'bleb.'
3. 3Observation: The patient must remain in the clinic for at least 30 minutes following administration to monitor for signs of an immediate hypersensitivity reaction or anaphylaxis.
4. 4Storage: Unopened vials should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

Since this product is typically used for one-time diagnostic testing or in a strictly controlled series, missed doses are handled by rescheduling the appointment. If a dose in an immunotherapy series is missed, the healthcare provider will determine if the dose needs to be 'backed up' to a lower concentration to ensure safety.

An overdose of Human Sputum, Bordetella Pertussis Infected can lead to severe localized reactions or systemic anaphylaxis.

• Signs of Overdose: Large, painful local swelling (Arthus-type reaction), generalized hives (urticaria), difficulty breathing (bronchospasm), rapid heart rate (tachycardia), and a significant drop in blood pressure (hypotension).
• Emergency Measures: If an overdose is suspected, the immediate administration of epinephrine (1:1000) is the primary treatment. Supportive care with antihistamines, corticosteroids, and intravenous fluids may be required.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to administer this product without medical guidance.

Most patients receiving Human Sputum, Bordetella Pertussis Infected will experience some form of local reaction, which is often the intended clinical result in diagnostic testing.

• Injection Site Erythema: Redness at the site of injection is very common. This usually appears within minutes and may peak at 24-48 hours.
• Induration and Swelling: A firm, raised bump at the injection site. It may feel tight or slightly warm to the touch.
• Pruritus (Itching): Intense itching at the site of administration is a frequent occurrence as the immune system responds to the antigens.
• Local Pain: A mild stinging or aching sensation during and immediately after the injection.

• Lymphadenopathy: Swelling of the lymph nodes near the injection site (e.g., in the axilla or armpit if the forearm was used).
• Low-grade Fever: A transient increase in body temperature as the body mounts an immune response.
• Malaise and Fatigue: A general feeling of being unwell or tired for 12-24 hours following the procedure.
• Headache: Mild to moderate tension-type headaches have been reported.

• Arthus Reaction: A localized vasculitis (inflammation of blood vessels) caused by the deposition of antigen-antibody complexes. This presents as severe pain, swelling, and sometimes tissue necrosis at the injection site, usually appearing several hours after administration.
• Persistent Granuloma: A small, hard knot that remains at the injection site for weeks or months.
• Vasovagal Syncope: Fainting or dizziness due to a reflex reaction to the needle or the procedure itself.

> Warning: Stop taking Human Sputum, Bordetella Pertussis Infected and call your doctor immediately if you experience any of these symptoms after your appointment.

• Anaphylaxis: This is a life-threatening allergic reaction. Symptoms include a sudden feeling of warmth, a 'feeling of impending doom,' swelling of the tongue or throat, wheezing, and fainting.
• Angioedema: Deep swelling under the skin, particularly around the eyes, lips, or extremities.
• Severe Bronchospasm: Sudden, intense difficulty breathing or a feeling of chest tightness.
• Generalized Urticaria: Hives that spread rapidly across the entire body, away from the injection site.
• Hypotension: A dangerous drop in blood pressure that may cause the patient to feel extremely weak or lose consciousness.

Because this agent is typically used for diagnostic or short-term purposes, long-term side effects are rare. However, repeated exposure to the pertussis toxin component could theoretically lead to:

• Persistent Sensitization: The patient may become permanently allergic to components of the extract.
• Altered Immune Reactivity: In rare cases, chronic exposure to bacterial toxins can modulate the immune system's baseline state, though this is primarily observed in the context of active infection rather than controlled clinical use.

There is currently no specific FDA Black Box Warning for 'Human Sputum, Bordetella Pertussis Infected' as a single entity; however, all standardized allergenic extracts carry a general warning regarding the risk of Severe Allergic Reactions.

Summary of General Allergenic Extract Warning: These products can cause severe systemic reactions, including anaphylaxis, which can be fatal. They should only be administered by healthcare providers experienced in the treatment of systemic reactions and in facilities equipped to handle such emergencies. Patients with unstable asthma or those taking beta-blockers may be at increased risk for severe outcomes if a reaction occurs.

Report any unusual symptoms to your healthcare provider. Your feedback is essential for monitoring the safety of biological products.

Human Sputum, Bordetella Pertussis Infected is a potent biological material. Its use is strictly limited to clinical environments where patients can be monitored for adverse reactions. Patients must provide a full medical history, specifically focusing on previous reactions to vaccines, insect stings, or respiratory infections.

No FDA black box warnings specifically for 'Human Sputum, Bordetella Pertussis Infected' exist at this time. However, the class-wide warning for Standardized Allergenic Extracts applies:

"Allergenic extracts may cause severe life-threatening systemic reactions, including anaphylactic shock and death. Patients must be observed for at least 30 minutes after administration. This product should only be used by physicians who are exceptionally familiar with the risks and management of systemic allergic reactions."

• Allergic Reactions / Anaphylaxis Risk: The primary risk is an immediate Type I hypersensitivity reaction. Patients with a history of severe allergies or multiple chemical sensitivities must be approached with extreme caution.
• Asthma Status: Patients with uncontrolled or severe asthma are at a significantly higher risk for a fatal outcome if a systemic reaction occurs. Asthma must be well-controlled before the administration of this extract.
• Infection Risk: Although the extract is standardized and processed to remove viable bacteria, it is derived from human sputum. There is a theoretical, albeit extremely low, risk of exposure to unidentified human pathogens. Modern manufacturing processes (filtration, heat treatment, or chemical inactivation) are designed to mitigate this risk.
• Neurological Effects: Because the pertussis toxin is an Acetylcholine Release Inhibitor, patients with pre-existing neuromuscular disorders (such as Myasthenia Gravis) should be monitored closely, as the toxin could theoretically exacerbate muscle weakness.

• Immediate Post-Injection Monitoring: Vital signs (blood pressure, heart rate, respiratory rate) should be checked before and 30 minutes after administration.
• Peak Flow Meter: For patients with asthma, a peak flow reading may be taken before and after the procedure to ensure no bronchoconstriction has occurred.
• Skin Reaction Assessment: The size of the wheal and flare (redness) must be measured and recorded at specific intervals (usually 15-20 minutes for immediate reactions and 24-48 hours for delayed reactions).

Patients should not drive or operate heavy machinery for at least 30-60 minutes after receiving the injection. If a systemic reaction occurs or if the patient feels dizzy or lightheaded, they should not drive until cleared by a physician.

Alcohol should be avoided for 24 hours before and after the administration of this extract. Alcohol can cause vasodilation, which may increase the rate of absorption of the antigens and potentially worsen a systemic allergic reaction.

If a patient experiences a systemic reaction, further use of the extract is usually contraindicated. If the extract is being used as part of a desensitization protocol, the healthcare provider will determine if the treatment should be permanently discontinued or if the dose should be significantly reduced.

> Important: Discuss all your medical conditions with your healthcare provider before starting Human Sputum, Bordetella Pertussis Infected.

• Beta-Blockers (e.g., Propranolol, Metoprolol): These medications are absolutely contraindicated in patients receiving potent allergenic extracts. Beta-blockers can make a patient unresponsive to the life-saving effects of epinephrine if anaphylaxis occurs. Furthermore, they may lower the threshold for anaphylaxis and increase the severity of bronchospasm.
• ACE Inhibitors (e.g., Lisinopril): These may increase the risk of severe systemic reactions and angioedema when combined with allergenic challenges.

• Immunosuppressants (e.g., Cyclosporine, Methotrexate, Prednisone): High-dose corticosteroids or other immunosuppressants can blunt the immune response, leading to false-negative results in diagnostic skin testing. Patients should ideally be off systemic steroids for at least 1-2 weeks before testing, depending on the dose.
• Anticholinergic Drugs (e.g., Atropine, Scopolamine): Since the extract contains an Acetylcholine Release Inhibitor, there may be an additive effect with other anticholinergic medications, potentially leading to increased dry mouth, urinary retention, or blurred vision.

• Antihistamines (e.g., Cetirizine, Diphenhydramine): These must be discontinued at least 3 to 7 days before diagnostic skin testing. Antihistamines will suppress the 'flare' (redness) and 'wheal' (swelling) response, rendering the diagnostic test useless.
• Tricyclic Antidepressants (TCAs) (e.g., Amitriptyline): TCAs have potent antihistamine properties and can interfere with skin test results for several weeks after discontinuation.

• High-Histamine Foods: Consuming foods high in histamine (such as aged cheeses, red wine, or fermented foods) shortly before testing may increase the baseline sensitivity of the skin and lead to exaggerated local reactions.
• Caffeine: Excessive caffeine intake may increase the heart rate and make the assessment of a systemic reaction more difficult.

• St. John's Wort: May affect the metabolism of various co-administered substances, although its direct interaction with biological extracts is poorly documented.
• Quercetin: This natural flavonoid has antihistamine properties and may interfere with the accuracy of diagnostic immunological tests.

• Interferon-Gamma Release Assays (IGRAs): The administration of this extract could theoretically cause a 'boosting' effect on other immunological tests that measure T-cell responses to bacterial antigens.
• Blood Glucose: The pertussis toxin component is known to induce 'islet-activating' effects, which can cause a transient drop in blood glucose followed by a rebound, potentially affecting the results of a glucose tolerance test.

For each major interaction, the mechanism typically involves either pharmacodynamic antagonism (e.g., antihistamines blocking the effect of histamine released by the extract) or potentiation of adverse effects (e.g., beta-blockers worsening anaphylaxis).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Human Sputum, Bordetella Pertussis Infected must NEVER be used in the following circumstances:

1. 1Previous Anaphylaxis to Pertussis-Containing Products: Any patient who has had a severe systemic reaction to a pertussis vaccine (DTaP, Tdap) or any extract containing Bordetella pertussis antigens must not receive this product.
2. 2Unstable Asthma: Patients with an FEV1 (Forced Expiratory Volume) of less than 70% of predicted or those with frequent exacerbations are at an unacceptably high risk for fatal bronchospasm.
3. 3Current Beta-Blocker Therapy: Due to the inability to treat anaphylaxis effectively with epinephrine.
4. 4Acute Infection: Administration during an active febrile illness can complicate the interpretation of results and may worsen the patient's clinical state.

These conditions require a careful risk-benefit analysis by the healthcare provider:

• Pregnancy: Unless the diagnostic information is critical for the immediate management of the mother's health.
• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may have unpredictable immune responses to bacterial extracts.
• Severe Dermatitis: If the skin at the site of testing is affected by eczema or psoriasis, the results will be uninterpretable.

Patients who are allergic to other members of the Standardized Insect Venom Allergenic Extract class (such as honeybee, yellow jacket, or hornet venom) may theoretically exhibit increased sensitivity to this extract due to shared biochemical pathways in the inflammatory response, although they are not antigenically identical.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Human Sputum, Bordetella Pertussis Infected.

Human Sputum, Bordetella Pertussis Infected is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this specific extract.

• Risks: The primary concern during pregnancy is the risk of maternal anaphylaxis, which can lead to fetal hypoxia (lack of oxygen) and preterm labor.
• Clinical Decision: It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Most elective diagnostic testing is postponed until after delivery.

It is not known whether the antigenic components or the pertussis toxin are excreted in human milk. Because many proteins are degraded in the maternal gastrointestinal tract if ingested, the risk to a nursing infant is likely low. However, caution should be exercised. The decision to breastfeed while receiving this extract should consider the importance of the diagnostic test to the mother and the potential for the infant to be exposed to maternal inflammatory mediators if a reaction occurs.

Safety and effectiveness in children under the age of 12 have not been established. In older children, the use is generally limited to specialized immunological workups. Because children have smaller airways, the risk of severe respiratory distress during an allergic reaction is higher than in adults.

Clinical studies of this extract did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

• Pharmacokinetic Changes: Reduced lymphatic flow and altered skin turgor in the elderly may slow the absorption of the extract.
• Polypharmacy: Elderly patients are more likely to be taking beta-blockers or ACE inhibitors, which are contraindications or major precautions.
• Cardiac Risk: The physiological stress of a systemic reaction is poorly tolerated by elderly patients with pre-existing coronary artery disease.

No dosage adjustment is required. However, the healthcare provider should be aware that uremia (high levels of urea in the blood) can suppress delayed-type hypersensitivity (DTH) skin reactions, potentially leading to a false-negative result.

No dosage adjustment is required. Hepatic function does not significantly impact the clearance or the immunological effect of this biological product.

> Important: Special populations require individualized medical assessment.

Human Sputum, Bordetella Pertussis Infected functions primarily through the biological activity of the Pertussis Toxin (PTX) and associated antigens. PTX is a classic A-B toxin. The B-pentamer binds to sialic acid-containing glycoproteins on the surface of most mammalian cells. After binding, the A-subunit (S1) is translocated into the cytoplasm.

In the cytoplasm, the S1 subunit acts as an ADP-ribosyltransferase. It targets the alpha-subunit of Gi proteins (inhibitory G proteins). By ADP-ribosylating a specific cysteine residue, the toxin locks the Gi protein in an inactive, GDP-bound state. This prevents the Gi protein from inhibiting adenylate cyclase, leading to an unregulated increase in intracellular cAMP. In neurons, this disruption specifically inhibits the calcium-dependent release of acetylcholine, which is the basis for its classification as an Acetylcholine Release Inhibitor.

• Dose-Response: The size of the skin reaction (wheal and flare) is directly proportional to the concentration of the extract and the patient's level of IgE or T-cell sensitivity.
• Onset of Effect: Immediate hypersensitivity (IgE-mediated) occurs within 15-20 minutes. Delayed-type hypersensitivity (T-cell mediated) occurs within 24-72 hours.
• Duration of Effect: The local inflammatory response typically resolves within 48-96 hours, but the immunological priming can persist for months.

| Parameter | Value |

|---|---|

| Bioavailability | High (Local), Low (Systemic) |

| Protein Binding | Significant (to cell surface receptors) |

| Half-life | 24-48 hours (Toxin subunits) |

| Tmax | 15-30 minutes (Local absorption) |

| Metabolism | Proteolytic degradation |

| Excretion | Renal (as peptide fragments) |

• Composition: A complex mixture of proteins, lipids, and polysaccharides. Key proteins include Pertussis Toxin (approx. 105 kDa), Filamentous Hemagglutinin (approx. 220 kDa), and Pertactin (69 kDa).
• Solubility: Soluble in aqueous buffers and physiological saline.
• Storage: Must be kept at 2-8°C to maintain the tertiary structure of the proteins, which is essential for biological activity.

This agent is uniquely categorized as a Standardized Insect Venom Allergenic Extract [EPC] due to its regulatory grouping and its use in immunological challenge. It also belongs to the Acetylcholine Release Inhibitor [EPC] class, reflecting its specific toxigenic mechanism. Related medications include other standardized allergenic extracts (e.g., Honey Bee Venom, Ragweed Extract) and other G-protein modulating toxins (e.g., Cholera Toxin).